Применение комбинированных препаратов с постоянными дозами антигипертензивных средств как начальная тактика лечения при повышенном уровне артериального давления: доказанные факты и мнение экспертов

Применение комбинированных препаратов с постоянными дозами антигипертензивных средств как начальная тактика лечения при повышенном уровне артериального давления: доказанные факты и мнение экспертов

Автор: Гиляревский С.Р., Бенделиани Н.Г., Голшмид М.В., Кузьмина И.М., Андреева И.Г.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Мнение эксперта

Статья в выпуске: 2, 2021 года.

Бесплатный доступ

В статье обсуждаются современные проблемы применения комбинированных антигипертензивных препаратов при реализации «тактики одной таблетки» у широкого круга пациентов с артериальной гипертонией. Приводятся результаты обсуждения такой проблемы экспертами, а также основные положения согласительного документа, посвященного подходам к реализации тактики более широкого использования комбинированных антигипертензивных препаратов, содержащих в одной таблетке 2 антигипертензивных средства или более. Рассматриваются как преимущества, так и ограничения «тактики одной таблетки». Обсуждаются результаты клинических исследований, которые подтверждают обоснованность использования комбинированной антигипертензивной терапии в качестве начальной тактики лечения большинства пациентов с артериальной гипертонией. Приводятся результаты оценки фармакоэкономических показателей при использовании комбинированной антигипертензивной терапии.

Еще

Артериальная гипертония, комбинированная антиги-пертензивная терапия, «тактика одной таблетки»

Короткий адрес: https://sciup.org/143176204

IDR: 143176204   |   DOI: 10.38109/2225-1685-2021-2-92-102

Список литературы Применение комбинированных препаратов с постоянными дозами антигипертензивных средств как начальная тактика лечения при повышенном уровне артериального давления: доказанные факты и мнение экспертов

  • GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environ- mental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923-1994. doi: 10.1016/ S0140-6736(18)32225-6.
  • Mills K.T, Bundy J.D, Kelly T.N., Reed J.E., Kearney P.M., Reynolds K, Chen J., He J. Global disparities of hypertension prevalence and con- trol: a systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441-450.
  • NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19^1 million participants. Lancet 2017;389(10064):37—55. doi: 10.1016/S0140-6736(16)31919-5. Erratum in: Lancet 2020;396(10255):886.
  • SPRINT Research Group, Wright J.T. Jr, Williamson J.D, Whelton PK, Snyder J.K, SinkK.M, Rocco M.V, Reboussin D.M., Rahman M, Oparil S, Lewis C.E., Kimmel P.L, Johnson K.C., Goff D.C. Jr, Fine LJ, Cutler J.A., Cushman W.C, Cheung A.K., Ambrosius W.T. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116. doi: 10.1056/NEJMoa1511939.
  • Vaduganathan M., Claggett B.L., Juraschek S.P., Solomon S.D. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 2020;5:576-581. doi: 10.1001/jamacardio.2019.6192.
  • Williamson J.D., Supiano M.A., Applegate W.B., Berlowitz D.R., Campbell R.C., Chertow G.M., Fine L.J., Haley W.E., Hawfield A.T., Ix J.H., Kitzman D.W., Kostis J.B, Krousel-Wood MA, Launer L.J., Oparil S., Rodriguez C.J., Roumie C.L., Shorr R.I, Sink KM, Wadley V.G., Whelton P.K, Whittle J, Woolard N.F., Wright J.T. Jr, Pajewski N.M.; SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >75 Years: A Randomized Clinical Trial. JAMA 2016;315:2673-2682. doi: 10.1001/ jama.2016.7050.
  • Whelton S.P, McEvoy J.W., Shaw L, Psaty BM, Lima J.A.C., Budoff M, Nasir K, Szklo M, Blumenthal R.S., Blaha M.J. Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors. JAMA Cardiol 2020;5:1011-1018. doi: 10.1001/jamacardio.2020.1731.
  • Unger T, Borghi C, Charchar F, Khan NA, Poulter N.R., Prabhakaran D, Ramirez A, Schlaich M., Stergiou G.S., Tomaszewski M., Wainford R.D., Williams B., Schutte A.E. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75:1334— 1357. doi: 10.1161/HYPERTENSI0NAHA.120.15026.
  • Zhang WR, Craven TE, Malhotra R, Cheung AK, Chonchol M, Drawz P, Sarnak MJ, Parikh CR, Shlipak MG, Ix JH; SPRINT Research Group. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. Ann Intern Med 2018;169:610-618. doi: 10.7326/M18-1037.
  • Cheung A.K., Rahman M., Reboussin D.M., Craven T.E., Greene T., Kimmel P.L., Cushman W.C, Hawfield A.T., Johnson K.C., Lewis C.E., Oparil S., Rocco M.V., Sink K.M., Whelton PK, Wright J.T. Jr, Basile J, Beddhu S., Bhatt U, Chang T.I., Chertow G.M., Chonchol M., Freedman B.I., Haley W, Ix J.H., Katz L.A, Killeen A.A., Papademetriou V, Ricardo A.C., Servilla K., Wall B., Wolfgram D., Yee J.; SPRINT Research Group. Effects of Intensive BP Control in CKD. J Am Soc Nephrol 2017;28:2812-2823. doi: 10.1681/ASN.2017020148.
  • Williamson J.D., Pajewski N.M., Auchus A.P, Bryan R.N., Chelune G., Cheung A.K., Cleveland M.L., Coker L.H., Crowe M.G., Cushman W.C, Cutler J.A., Davatzikos C., Desiderio L., Erus G., Fine L.J., Gaussoin SA., Harris D., Hsieh M.K., Johnson K.C., KimmelP.L., Tamura M.K., Launer L.J., Lerner A.J., Lewis C.E., Martindale-Adams J, Moy C.S., Nasrallah I.M., Nichols L.O., Oparil S., Ogrocki P.K., Rahman M., Rapp S.R., Reboussin D.M., Rocco M.V, Sachs B.C., Sink K.M., Still C.H., Supiano MA, Snyder J.K., Wadley V.G., Walker J, Weiner D.E., Whelton PK, Wilson V.M., Woolard N, Wright J.T. Jr, Wright C.B. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA 2019;321:553-561. doi: 10.1001/jama.2018.21442.
  • Juraschek S.P., Taylor AA, Wright J.T. Jr, Evans G.W., Miller E.R. 3rd, Plante T.B, Cushman W.C., Gure T.R., Haley WE, Moinuddin I., Nord J, Oparil S., Pedley C, Roumie C.L., Whittle J, Wiggers A, Finucane C., Anne Kenny R., Appel L.J., Townsend R.R.; SPRINT Research Group. Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT. Hypertension. 2020;75:660-667. doi: 10.1161/HYPERTENSI0NAHA.119.14309.
  • Muntner P., Hardy S.T., Fine L.J., Jaeger B.C., Wozniak G., Levitan E.B., Colantonio L.D. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA 2020;324:1190-1200. doi: 10.1001/jama.2020.14545.
  • Campana E., Cunha V, Glaveckaite S., Gruev I., Lamirault G., Lehmann E., MasiS., Mfeukeu Kuate L., Mishshenko L., Ona D.I.D., Oo M.Z., Tautu O.G.F., Vachulova A, Vintila A.M., Wolf J, Zvartau N, Narkiewicz K., Laurent S. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens 2020 Aug 21. doi: 10.1097/HJH.0000000000002598.
  • Thoenes M., Neuberger H.R., Volpe M, Khan B.V., Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24:336— 344. doi: 10.1038/jhh.2009.76.
  • Cushman W.C, Ford C.E., Cutler JA., Margolis K.L., Davis B.R., Grimm R.H., Black H.R., Hamilton B.P., Holland J, Nwachuku C., Papademetriou V, Probstfield J, Wright J.T. Jr, Alderman M.H., Weiss R.J., Piller L, Bettencourt J., Walsh S.M. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404. doi: 10.1111/j.1524-6175.2002.02045.x.
  • ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997. doi: 10.1001/jama.288.23.2981.
  • Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H, Nieminen M.S., Omvik P., Oparil S, Wedel H.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995—1003. doi: 10.1016/S0140-6736(02)08089-3.
  • Wald D.S., Law M, Morris J.K., Bestwick J.P., Wald N.J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290—300. doi: 10.1016/j.amjmed.2008.09.038.
  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D.L., Coca A, de Simone G, Dominiczak A, Kahan T, MahfoudF, Redon J., Ruilope L, ZanchettiA, Kerins M, Kjeldsen S.E., Kreutz R, Laurent S, Lip G.Y.H, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R.E., Shlyakhto E, Tsioufis C, Aboyans V, Desormais .I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39:3021— 3104. doi: 10.1093/eurheartj/ehy339.
  • Rea F., Corrao G., Merlino L., Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018; 72:846—853. doi: 10.1161/HYPERTENSI0NAHA.118.11308.
  • Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L, Hua T, Laragh J.H., McInnes G.T., Mitchell L, Plat F, Schork MA, Smith B., Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049—2051. doi: 10.1016/S0140-6736(04)16456-8.
  • Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875— 886. doi: 10.1097/00004872-200305000-00011.
  • Cifkova R., Erdine S., Fagard R., Farsang C., Heagerty A.M., Kiowski W, Kjeldsen S., Luscher T., Mallion J.M., Mancia G, Poulter N., Rahn K.H., Rodicio J.L., Ruilope L.M., van Zwieten P., Waeber B., Williams B., Zanchetti A.; ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779—1786. doi: 10.1097/01. hjh0000084773.37215.1b.
  • The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413—2446. doi: 10.1001/archinte.157.21.2413.
  • Mancia G., Rea F., Corrao G., Grassi G. Two-drug combinations as firststep antihypertensive treatment. Circ Res 2019;124:1113—1123. doi: 10.1161/CIRCRESAHA.118.313294.
  • Corrao G., Nicotra F., Parodi A., Zambon A., Heiman F., Merlino L., Merlino L., Fortino I., Cesana G., Mancia G. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58:566—572. doi: 10.1161/ HYPERTENSIONAHA.111.177592.
  • GradmanA.H., Parise H, Lefebvre P., FalveyH, Lafeuille M.H., Duh M.S. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61:309—318. doi: 10.1161/HYPERTENSI0NAHA.112.201566.
  • Rea F., Corrao G., Merlino L., Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018; 39:3654—3661. doi: 10.1093/eurheartj/ ehy420.
  • BronsertM.R., Henderson W.G., ValuckR., Hosokawa P., Hammermeister K. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. J Am Board Fam Med 2013;26:529—538. doi: 10.3122/jabfm.2013.05.130048.
  • Egan B.M., Bandyopadhyay D., Shaftman S.R., Wagner C.S., Zhao Y, Yu-Isenberg K.S. Initial monotherapy and combination therapy and hyper- tension control the first year. Hypertension 2012;59:1124— 1131. doi: 10.1161/HYPERTENSI0NAHA.112.194167.
  • Verma A.A, Khuu W, Tadrous M., Gomes T, Mamdani M.M. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort study. PLoS Med 2018;15:e1002584. doi: 10.1371/journal.pmed.1002584.
  • Belsey J.D. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ 2012;15:897—905. doi: 103111/13696998.2012689792.
  • Corrao G., Parodi A., Nicotra F., Zambon A, Merlino L., Cesana G., Mancia G. Better compliance to antihypertensive medications reduces cardio-vascular risk. J Hypertens 2011;29:610-618. doi: 10.1097/ HJH.0b013e328342ca97.
  • Claxton A.J., Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310. doi: 10.1016/s0149-2918(01)80109-0.
  • Gupta P., Patel P., Strauch B, Lai F.Y., AkbarovA, Maresovä V, White C.M.J., Peträk O., Gulsin G.S., Patel V., Rosa J., Cole R, Zelinka T, Holaj R., Kinnell A, Smith P.R., Thompson J.R., Squire I., Widimsky J. Jr, Samani N.J., Williams B., Tomaszewski M. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017;69:1113-1120. doi: 10.1161/HYPERTENSI0NAHA.116.08729.
  • Sherrill B., Halpern M., Khan S., Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of healthcare costs and adherence. J Clin Hypertens (Greenwich) 2011;13:898-909. doi: 10.1111/j.1751-7176.2011.00550.x.
  • Du L.P., Cheng Z.W., Zhang Y.X., Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich) 2018;20:902— 907. doi: 10.1111/jch.13272.
  • Kawalec P., Holko P., Gawin M., Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci 2018;14:1125-1136. doi: 10.5114/ aoms.2018.77561.
  • Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427. doi: 10.1136/ bmj326.7404.1427.
  • Bennett A, Chow C.K., Chou M, Dehbi H.M., Webster R., Salam A., Patel A., Neal B., Peiris D., Thakkar J., Chalmers J., Nelson M., Reid C., Hillis G.S., Woodward M., Hilmer S., Usherwood T., Thom S., Rodgers A. Efficacy and safety of quarter-dose blood pressure-lowering agents: a systematic review and meta-analysis of randomized controlled trials. Hypertension 2017; 70:85-93. doi: 10.1161/ HYPERTENSI0NAHA.117.09202.
  • Messerli F.H. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002;4:479-482. doi: 10.1007/s11886-002-0110-9.
  • Makani H., Bangalore S., Romero J, Wever-Pinzon O., Messerli F.H. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128-135. doi: 10.1016/j.amjmed.2010.08.007.
  • Patel A.; ADVANCE Collaborative Group, MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., Harrap S., Poulter N., Marre M., Cooper M., Glasziou P., Grobbee D.E., Hamet P., Heller S., Liu L.S., Mancia G., Mogensen C.E., Pan C.Y., Rodgers A., Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829—840. doi: 10.1016/S0140-6736(07)61303-8.
  • Chalmers J., Arima H., Woodward M., Mancia G., Poulter N., Hirakawa Y., Zoungas S., Patel A, Williams B., Harrap S. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63:259-264. doi: 10.1161/ HYPERTENSI0NAHA.113.02252.
  • Кобалава Ж. Д., Виллевальде С. В., Боровкова Н. Ю., Шутов А. М., Ничик Т. Е., Сафуанова Г. Ш. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017;57(10):39—44. [Kobalava Zhanna D., Villevalde S.V., Borovkova N. Yu., Shutov A.M., Nichik T.E., Safuanova G. Sh. Prevalence of markers of chronic kidney disease in patients with arterial hypertension: results of epidemiological study CHRONOGRAF (in Russ.)] doi.org/10.18087/ cardio.2017.10.10041.
  • Глезер М.Г., Деев АД. от имени участников программы ФОРСАЖ. Как увеличить эффективность антигипертензивной терапии в реальной клинической практике: результаты российской наблюдательной программы ФОРСАЖ. Кардиология2016;56:18-24. [Glezer M.G., Deev A.D. How to increase the effectiveness of antihypertensive therapy in clinical practice: results of the russian observational program forsazh (in Russ.)]doi: http://dx.doi.org/10.18565/cardio.2016.1.13-24.
  • Dezsi CA, Glezer M, Karpov Y, Brzozowska-Villatte R, Farsang C. Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies. Adv Ther 2020 Nov 5. doi: 10.1007/s12325-020-01527-3.
  • Abraham G, Dezsi CA. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther. 2017;34(7):1753-63. doi:10.1007/s12325-017-0572-1.
  • Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014;34(10):701-8. doi:10.1007/ s40261-014-0223-0.
  • Toth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2.
  • Кобалава Ж.Д., Троицкая ЕА., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпо-нентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018;58(9):21—30. [Kobalava Z.D., Troitskaya E.A., Tolkacheva V.V. Combined Therapy of Arterial Hypertension With a Triple Fixed-Dose Combination of Amlodipine/Indapamide/ Perindopril Arginine in Real Clinical Practice: the Organization and the Main Results of the DOKAZATEL'STVO (Proof) Study. Kardiologiia. 2018;58(9):21-30. (In Russ.)] doi:10.18087/cardio.2018.9.10170.
  • Недогода С.В., Чумачек Е.В., Ледяева А.А., Цома В.В., СаласюкА.С., Смирнова В.О., Хрипаева В.Ю., Палашкин Р.В. Возможности фиксированной комбинации амлодипина, индапамида и периндопри-ла у пациентов с неконтролируемой артериальной гипертензией. Кардиология. 2017;57(6):29—32. [Nedogoda S.V., Chumachek E.V., Tsoma V.V., Salasyuk A.S., Smirnova V.O., Hripaeva V.J., Palashkin R.V., Popova E.A. Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. «Arterial'naya Gipertenziya» («Arterial Hypertension»). 2018;24(3):369-378. (In Russ.)] https://doi. org/10.18565/cardio.2017.6.29-32.
  • Карпов Ю.А., Горбунов В.М., Логунова Н.А. от имени группы исследователей исследования ТРИКОЛОР. Применение тройной фиксированной комбинации в лечении артериальной гипертен-зии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования ТРИКОЛОР. Российский кардиологический журнал 2020;25(10):4130. [Karpov Yu.A., Gorbunov V.M., Logunova N.A. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020;25(10):4130. (In Russ.)] doi:10.15829/1560-4071-2020-4130.
  • Drexel C, Merlo K., Basile J.N., Watkins B, Whitfield B., Katz J.M., Pine B., Sullivan T. Highly interactive multisession programs impact physician behavior on hypertension management: outcomes of a new CME model. J Clin Hypertens (Greenwich) 2011;13:97—105. doi: 10.1111/j.1751-7176.2010.00399x.
  • Cervero R.M., Gaines J.K. The impact of CME on physician performance and patient health outcomes: an updated synthesis of systematic reviews. J Contin Educ Health Prof 2015; 35:131—138. doi: 10.1002/ chp.21290.
  • van Bussel E., Reurich L., Pols J., Richard E., Moll van Charante E., Ligthart S. Hypertension management: experiences, wishes and concerns among older people — a qualitative study. BMJ Open 2019;9:e030742.
  • Matthews A, Herrett E., Gasparrini A., Van Staa T., Goldacre B., Smeeth L., Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ 2016; 353:i3283. doi: 10.1136/bmj.i3283.
  • Marcu A., Black G., Whitaker K. Variations in trust in Dr Google when experiencing potential breast cancer symptoms: exploring motivations to seek health information online. Health Risk Soc 2018; 20:325—341. https://doi.org/10.1080/13698575.2018.1550742.
  • Alessa T., Hawley M.S., Hock E.S., de Witte L. Smartphone apps to support self-management of hypertension: review and content analysis. JMIR Mhealth Uhealth 2019; 7:e13645. doi: 10.2196/13645.
  • Cherrez-Ojeda I., Vanegas E, Felix M, Mata V.L., Gavilanes A.W, Chedraui P. Use and preferences of information and communication technologies in patients with hypertension: a cross-sectional study in Ecuador. J Multidiscip Healthc 2019; 12:583 - 590. doi: 102147/JMDH. S208861.
  • Volk R., Obeid N. What can we do about Dr Google? Using the electronic medical record (EMR) to prescribe reliable online patient education. J Med Libr Assoc 2019; 107:606 - 608. doi: 10.5195/jmla.2019.774.
  • Johnson H.M, LaMantia J.N, Brown CM, Warner R.C., Zeller L.M, Haggart R.C, Stonewall K, Lauver D.R. My Hypertension Education and Reaching Target (MyHEART): development and dissemination of a patient-centered website for young adults with hypertension. JMIR Cardio 2017; 1:e5. doi: 10.2196/cardio.8025.
  • Dunn P.H., Woo B.K.P. Facebook recruitment of Chinese-speaking participants for hypertension education. J Am Soc Hypertens 2018; 12:690 - 692. doi: 10.1016/j.jash.2018.06.017.
  • Hui C.Y., Creamer E, Pinnock H, McKinstry B. Apps to support self-management for people with hypertension: content analysis. JMIR Mhealth Uhealth 2019; 7:e13257. doi: 10.2196/13257.
  • Bushardt R.L, Massey E.B., Simpson T.W, Ariail J.C., Simpson K.N. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008; 3:383—389. doi: 10.2147/cia.s2468.
  • Nowak E, Happe A, Bouget J., Paillard F., Vigneau C., Scarabin P.Y., Oger E. Safety of fixed dose of antihypertensive drug combinations compared to (single pill) free-combinations: a nested matched case-control analysis. Medicine (Baltimore) 2015; 94:e2229. doi: 10.1097/ MD.0000000000002229.
  • Juraschek S.P., Hu J.R, Cluett J.L, Ishak A, Mita C, Lipsitz LA, Appel L.J., Beckett N.S., Coleman R.L., Cushman W.C., Davis B.R., Grandits G., Holman R.R., Miller E.R., Peters R, Staessen JA, Taylor AA, Thijs L., Wright J.T. Jr, Mukamal K.J. Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. Ann Intern Med. 2020 Sep 10. doi: 10.7326/M20-4298. Epub ahead of print.
  • Williamson J.D., Supiano MA, Applegate W.B., Berlowitz D.R., Campbell R.C, Chertow GM, Fine L.J., Haley WE, Hawfield A.T, Ix J.H., Kitzman D.W., Kostis J.B., Krousel-Wood MA, Launer L.J., Oparil S, Rodriguez C.J, Roumie C.L, Shorr R.I., Sink K.M., Wadley V.G., Whelton P.K., Whittle J., Woolard NE, Wright J.T. Jr, Pajewski N.M.; SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >75 Years: A Randomized Clinical Trial. JAMA. 2016;315:2673—7382. doi: 10.1001/ jama.2016.7050.
  • Lauffenburger J.C., Landon J.E., Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med 2017;32:619—625. doi: 10.1007/s11606-016-3972-z.
  • Chen X, Hu P., Jiang J., Liu T., Zhong W, Liu H, Zhao Q. Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Clin Drug Investig 2012;32:783—790. doi: 10.1007/s40261-012-0026-0.
  • Noh Y.H., Lim H.S., Kim M.J, Kim Y.H., Choi H.Y., Sung H.R., Jin S.J., Lim J., Bae K.S. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Clin Ther 2012;34:1625—1635. doi: 10.1016/j. clinthera.2012.05.010.
  • Bowles N.P., Thosar S.S., Herzig M.X., Shea S.A. Chronotherapy for hypertension. Curr Hypertens Rep 2018; 20:97. doi: 10.1007/s11906-018-0897-4.
  • Akazawa M., Eukuoka K. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Serv Res 2013;13:124. doi: 10.1186/14726963-13-124. doi: 10.1186/1472-6963-13-124.
  • Brixner D.I., Jackson K.C. 2nd, Sheng X, Nelson R.E., Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008;24:2597—2607. doi: 10.1185/03007990802319364.
  • Hong S.H., Wang J., Tang J. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy. Am J Hypertens 2013;26:879-887. doi: 10.1093/ajh/hpt035.
  • Rabbani A., Alexander G.C. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens 2008;21:509— 513. doi: 10.1038/ajh.2008.31.
  • Stankus V, Hemmelgarn B., Campbell N.R., Chen G., McAlister FA., Tsuyuki R.T. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009;16:e151-e155.
  • Bress A.P, Bellows B.K., King J.B., Hess R, Beddhu S., Zhang Z., Berlowitz D.R., Conroy M.B., Fine L, Oparil S., Morisky D.E., Kazis L.E., Ruiz-Negrön N, Powell J, Tamariz L., Whittle J., Wright J.T. Jr, Supiano M.A., Cheung A.K., Weintraub W.S., Moran A.E.; SPRINT Research Group. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med 2017; 377:745-755. doi: 10.1056/ NEJMsa1616035.
  • Tung Y.C., Lin Y.S., Wu L.S., Chang C.J., Chu P.H. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens (Greenwich) 2015;17:51-58. doi: 10.1111/jch.12449.
  • Machnicki G, Ong S.H., Chen W, Wei Z.J., Kahler K.H. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. Curr Med Res Opin 2015;31:2287-2296. doi: 10.1185/03007995.2015.1098598.
  • Panjabi S., Lacey M., Bancroft T., Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 2013;7:46-60. doi: 10.1016/j.jash.2012.11.001.
  • Hagendorff A., Freytag S., Muller A, Klebs S. Pill burden in hypertensive patients treated with single-pill combination therapy —an observational study. Adv Ther 2013; 30:406-419. doi: 10.1007/s12325-013-0018-3.
  • World Health Organization. Essential medicines selection. An application to include blood pressure lowering drug fixed dose combinations to the model list of essential medicines lists for the treatment of essential hypertension in adults. Available from: https:// www.who.int/ selection_medicines/committees/expert/22/fixed-dose_combination_ antihypertensives/en/ [Accessed 2018]
  • World Health Organization. WHO drug information. WHO Drug Inf2002; 17:143-227.
  • Клинические рекомендации МЗ РФ «Артериальная гипертензия у взрослых». [Clinical guidelines of the Russian Ministry of health «Arterial hypertension in adults» (in Russ.)] https://www.scardio.ru/ content/Guidelines/Clinic_rek_AG_2020.pdf
Еще
Статья научная
SciUp 2024 © 2024 ©